Jim Cramer defends Amgen's stock after drop, highlighting benefits of new drug

From Yahoo Finance: 2025-06-28 12:20:00

In a recent analysis, Jim Cramer discussed Wall Street’s reaction to Amgen Inc.’s (NASDAQ: AMGN) latest data announcement on MariTide. Despite the stock selling off post-announcement, Cramer highlighted the benefits of MariTide’s monthly injection compared to weekly injections of other drugs like Mounjaro or Ozempic.

Amgen (NASDAQ: AMGN) is a biotechnology company known for developing and marketing human therapeutics. Their portfolio includes treatments for various conditions such as rheumatoid arthritis, psoriasis, osteoporosis, cancer, cardiovascular disease, and rare disorders. A pharmacist filling a prescription for one of their complex drugs exemplifies their commitment to innovation and patient care.

Read more: Jim Cramer Says That Amgen’s Stock “Did Not Deserve to Get Hit This Hard”